4basebio (LSE:4BB), the Cambridge-based supplier of synthetic DNA for genetic medicines, reported a sharp fall in first-half Revenue in its half-year report for the six months to 30 June 2026, which it attributed to project delays. The company nonetheless pointed to a much larger Business pipeline and said it expected significant revenue growth in the second half of 2026 and into 2027.
What the company does
4basebio develops and manufactures synthetic DNA products used in the production of gene therapies, mRNA medicines and DNA vaccines. Its enzymatic Manufacturing process is designed as an alternative to traditional plasmid DNA made in bacteria, with potential advantages in speed and purity. The company supplies research-use material and is building capacity to provide high-quality DNA suitable for clinical use. It is also developing a non-viral delivery technology, known as the Hermes nanoparticle platform.
Latest developments
According to the half-year report, revenue fell to about £0.3 million from £1.2 million a year earlier and the loss for the period was around £8.9 million, reflecting what the company described as strategic investments. Cash stood at roughly £14.1 million at the end of June, which the company said provided runway into late 2027 following a €7 million Loan drawdown. The qualified business pipeline rose about sixfold to £63 million, and sales orders were up 210% to £1.2 million.
Earlier in the year, 4basebio announced the Lease of a new manufacturing Facility in Cambridge to support growing demand, signed a clinical Supply agreement in May 2026 to support a phase II clinical trial, and launched a high-capacity single-stranded DNA platform. The company has also announced a Marketing collaboration with US-based Genezen, news that sent the shares higher.
Leadership changes
In February 2026, the company promoted chief operating officer Amy Walker to chief executive, succeeding founder Heikki Lanckriet, who stepped down after six years to lead a new entity focused on taking the Hermes nanoparticle platform into the clinic, while remaining on the board. Chief financial officer David Roth was also set to join the new entity after a handover period, and the company has since named Richard Bungay as CFO. The shares rose 13% to 630p on the day the Leadership changes were announced.
Financial picture
4basebio remains in an Investment phase, with losses well above revenue. The loan drawdown extends its cash runway but adds Debt to the balance sheet. The company does not pay a dividend.
Sector and index context
4basebio (LSE:4BB) is one of the life sciences constituents of the FTSE AIM All Share Index whose valuation rests largely on future growth rather than current revenue. The genetic medicine supply chain has been affected by tighter biotech funding, which can delay client projects, a Factor the company cited for its weaker first half. At the same time, Demand for faster and more scalable DNA manufacturing is a long-term theme across the sector.
Key risks
The main risks are execution and timing: converting the pipeline into revenue depends on client projects proceeding as planned. The company is loss-making and may need further funding beyond 2027 if growth disappoints. Management transition, competition from established plasmid DNA suppliers, and regulatory hurdles for clinical-grade material also matter.
What to watch next
Investors will look for evidence of the promised second-half revenue growth, further clinical supply agreements and progress at the new Cambridge facility, with full-year results for 2026 expected next year.






Please wait processing your request...